| Not Yet Recruiting | Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregiv NCT07454733 | Trustees of Dartmouth College | N/A |
| Recruiting | Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) NCT07521930 | Johns Hopkins University | N/A |
| Not Yet Recruiting | Resiliency Intervention for Patients With ALS and Their Care-Partners NCT06968468 | Massachusetts General Hospital | N/A |
| Not Yet Recruiting | A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS) NCT07071935 | University of Pennsylvania | Phase 2 |
| Enrolling By Invitation | HEALEY ALS Platform Trial - Regimen I NUZ-001 NCT07410806 | Merit E. Cudkowicz, MD | Phase 2 / Phase 3 |
| Enrolling By Invitation | Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS NCT07298486 | Nova Southeastern University | N/A |
| Not Yet Recruiting | A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. NCT07369076 | Nura Bio | Phase 1 / Phase 2 |
| Recruiting | Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With NCT07187388 | Nova Southeastern University | N/A |
| Recruiting | Intestinal Microbiome Transplant in ALS NCT07017946 | Duke University | Phase 1 / Phase 2 |
| Recruiting | Healing ALS Registry Observational Study (HAROS) NCT07233148 | Healing Advocates Registry and Ministry | — |
| Not Yet Recruiting | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients NCT07174492 | AB Science | Phase 3 |
| Not Yet Recruiting | A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS NCT07169175 | SineuGene Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS NCT07142291 | PhenoNet, Inc. | Phase 2 |
| Recruiting | Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis NCT07257302 | National Center of Neurology and Psychiatry, Japan | N/A |
| Not Yet Recruiting | Safety Study of XT-150 in Participants With ALS NCT06704347 | Xalud Therapeutics, Inc. | Phase 1 |
| Recruiting | Study of COYA 302 for the Treatment of ALS NCT07161999 | Coya Therapeutics | Phase 2 |
| Not Yet Recruiting | FHND1002 for ALS Treatment: Phase 2 NCT07138014 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis NCT07023835 | Zydus Therapeutics Inc. | Phase 2 |
| Recruiting | The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjec NCT07118319 | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Dynamic Impact of NIV on Diaphragmatic Ultrasound in Patients With Amyotrophic Lateral Sclerosis NCT07170865 | University Hospital, Grenoble | — |
| Not Yet Recruiting | Generation of Cell Banks and Biomarker Isolation From Patients With Amyotrophic Lateral Sclerosis (ALS) (HCD-S NCT07099066 | Human Cell Design | — |
| Not Yet Recruiting | HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial NCT06719947 | Universidade Federal do Rio Grande do Norte | Phase 2 / Phase 3 |
| Not Yet Recruiting | Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS NCT07080801 | Beijing Tiantan Hospital | EARLY_Phase 1 |
| Recruiting | GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Contr NCT07127172 | Neuralink Corp | N/A |
| Not Yet Recruiting | Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presen NCT06973629 | Brainstorm-Cell Therapeutics | Phase 3 |
| Terminated | Extension Study of Participants From SPG302-ALS-001 NCT06903286 | Spinogenix | Phase 2 |
| Recruiting | Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resi NCT07202494 | Assistance Publique Hopitaux De Marseille | — |
| Recruiting | UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of NCT06992596 | Neuralink Corp | N/A |
| Recruiting | The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patient NCT06765499 | First People's Hospital of Hangzhou | N/A |
| Recruiting | Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis NCT06877143 | University of Ulm | N/A |
| Not Yet Recruiting | Individualized Functional Imaging-Guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Post NCT06819358 | Peking University Third Hospital | EARLY_Phase 1 |
| Recruiting | Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Earl NCT06803784 | Neuromed IRCCS | — |
| Recruiting | Examining Interactions Between PALS and Caregivers NCT06819124 | Penn State University | N/A |
| Recruiting | [18F]ACI-19626 PET in TDP-43 Proteinopathies NCT06891716 | AC Immune SA | EARLY_Phase 1 |
| Recruiting | A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS NCT06849609 | Hong Chen | EARLY_Phase 1 |
| Not Yet Recruiting | Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients with Amyotrophic Lateral Scl NCT06608004 | Centre Hospitalier Universitaire Dijon | — |
| Recruiting | Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sc NCT06834269 | Campus Bio-Medico University | N/A |
| Enrolling By Invitation | Control of Assistive Devices Via Brain-Computer Interface Technology NCT06710626 | Neuralink Corp | N/A |
| Recruiting | Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases NCT06671236 | Novabio Therapeutics | Phase 1 |
| Recruiting | CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices NCT06700304 | Neuralink Corp | N/A |
| Recruiting | Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study NCT06681610 | Parc de Salut Mar | N/A |
| Recruiting | Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerv NCT07268833 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | — |
| Active Not Recruiting | A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) NCT06643481 | Novartis Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal I NCT06645197 | Peking University Third Hospital | EARLY_Phase 1 |
| Recruiting | Identification of Early Markers for ALS NCT07213440 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Active Not Recruiting | Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Scler NCT06493279 | RJK Biopharma Ltd | Phase 1 |
| Recruiting | Quantification of Hsp90 in the Human Brain NCT07380204 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Recruiting | First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With NCT06351592 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations NCT06849115 | ChaodongWang | Phase 4 |
| Enrolling By Invitation | Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults NCT06782958 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis NCT06429059 | Duke University | Phase 2 |
| Recruiting | A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 NCT05995782 | 1ST Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial NCT04244630 | Dallas VA Medical Center | Phase 2 |
| Recruiting | A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS NCT06917924 | A.O.U. Città della Salute e della Scienza | — |
| Recruiting | Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers NCT05395624 | Ashvattha Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis NCT04505358 | Samus Therapeutics, Inc. | Phase 2 |
| Completed | A First in Human Study of ORT247 in Healthy Volunteers NCT06769620 | Orthogonal Neuroscience Inc. | Phase 1 |
| Enrolling By Invitation | Quest to Analyze One Thousand Humans Meditating NCT06583395 | Tobias Moeller-Bertram | — |
| Completed | Remotely Supervised tDCS for Slowing ALS Disease Progression NCT04866771 | University of Illinois at Chicago | N/A |
| Active Not Recruiting | Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry NCT07143656 | Biocells Medical | — |
| Completed | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) NCT04577404 | Tanabe Pharma America, Inc. | Phase 3 |
| Recruiting | UPenn Observational Research Repository on Neurodegenerative Disease NCT04715399 | University of Pennsylvania | — |
| Withdrawn | Biomarkers in Neurodegenerative Diseases NCT04055532 | University of Minnesota | — |
| Suspended | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease NCT04031469 | ProgenaBiome | — |
| Unknown | Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS NCT03800524 | Humanitas Mirasole SpA | Phase 3 |
| Suspended | A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV NCT03755167 | Immunity Pharma Ltd. | Phase 2 |
| Terminated | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) NCT03580616 | Elijah W. Stommel | Phase 2 |
| Completed | Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease NCT03645031 | University of Florida | N/A |
| Unknown | Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) NCT03088839 | Neuromed IRCCS | — |
| Completed | Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients NCT03280056 | Brainstorm-Cell Therapeutics | Phase 3 |
| Recruiting | Retinal Imaging in Neurodegenerative Disease NCT03233646 | Duke University | — |
| Completed | A Study for Patients Who Completed VITALITY-ALS (CY 4031) NCT02936635 | Cytokinetics | Phase 3 |
| Completed | Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis NCT02559869 | Massachusetts General Hospital | — |
| Completed | Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS NCT02469675 | Bronx VA Medical Center | N/A |
| Unknown | Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational NCT02424669 | Assistance Publique Hopitaux De Marseille | N/A |
| Unknown | A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction D NCT02463825 | University of Calgary | Phase 2 |
| Completed | F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis NCT02414230 | Tammie L. S. Benzinger, MD, PhD | — |
| Unknown | A Study to Evaluate the Performance of a Diagnostic Test in ALS NCT02759913 | Iron Horse Diagnostics, Inc. | — |
| Completed | "New Perspectives of Adaptation to NIV in ALS" NCT02537132 | Fondazione Don Carlo Gnocchi Onlus | N/A |
| Completed | Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) NCT02365922 | University of California, San Francisco | — |
| Completed | Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients NCT02152449 | University Hospital, Limoges | N/A |
| Completed | Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patient NCT02017912 | Brainstorm-Cell Therapeutics | Phase 2 |
| Completed | Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode NCT01746381 | Marta Kaminska | N/A |
| Completed | Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) NCT01786603 | Richard Barohn, MD | Phase 2 |
| Completed | Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders NCT02118805 | Beth Israel Deaconess Medical Center | — |
| Completed | Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) NCT01884571 | Emory University | Phase 2 |
| Completed | PET Imaging in ALS Patients NCT02236897 | Johns Hopkins University | N/A |
| Completed | Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) NCT01938495 | Barrow Neurological Institute | Phase 2 |
| Withdrawn | Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS) NCT01945853 | Johns Hopkins University | N/A |
| Completed | Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclero NCT02588677 | AB Science | Phase 2 / Phase 3 |
| Completed | Clinical Trial Nuedexta in Subjects With ALS NCT01806857 | Center for Neurologic Study, La Jolla, California, | Phase 2 |
| Completed | Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography NCT01803386 | Skulpt, Inc. | — |
| Unknown | Determining the Safety of L-serine in ALS NCT01835782 | Phoenix Neurological Associates, LTD | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease NCT01776970 | Ospedale San Raffaele | Phase 2 / Phase 3 |
| Completed | DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic NCT01699451 | Mayo Clinic | — |
| Completed | Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Scl NCT01605006 | Synapse Biomedical | N/A |
| Completed | Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis NCT01492686 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) NCT01232738 | Yunxia Wang, MD | Phase 2 |
| Completed | A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery NCT01592552 | Sanguine Biosciences | — |
| Completed | PRISM Registry: Pseudobulbar Affect Registry Series NCT01366027 | Avanir Pharmaceuticals | — |
| Completed | Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) NCT00876772 | Charite University, Berlin, Germany | Phase 2 / Phase 3 |
| Completed | Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis NCT01277315 | Charite University, Berlin, Germany | Phase 2 |
| Completed | A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnos NCT00694941 | Ono Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) NCT00445172 | Eisai Co., Ltd. | Phase 2 / Phase 3 |
| Terminated | Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) NCT01363882 | Columbia University | N/A |
| Completed | A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) NCT00444613 | Eisai Co., Ltd. | Phase 2 / Phase 3 |
| Completed | Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (AL NCT00424463 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Cla NCT00415519 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Scleros NCT00403104 | Ono Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) NCT00330681 | Tanabe Pharma Corporation | Phase 3 |
| Terminated | Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) NCT00231140 | Charite University, Berlin, Germany | Phase 2 |
| Completed | A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS NCT00244244 | CytRx | Phase 2 |
| Unknown | Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS) NCT00420719 | Synapse Biomedical | N/A |
| Unknown | Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis NCT00069186 | The Avicena Group | Phase 3 |
| Completed | Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] NCT00214110 | University of Wisconsin, Madison | Phase 2 |
| Completed | Genetics of Familial and Sporadic ALS NCT00821132 | Northwestern University | — |